The studies suggest, as others have said, that the Lantus does not quite last the full 24 hours and 5% of folk need to take Lantus BD. Agree that Lantus can sting, it is slightly acidic to keep it soluble in the cartridge. If my patients were having bother with Lantus, I would switch to tresiba degludec and generally it was an improvement; I think Marc Evans of cardiff published his similar real world experience of switching to degludec. Degludec has dropped price in UK, but it is still more expensive than other long acting analogues. There is a good deal of flexibility in timing of the degludec dosse, which is useful if absent minded, busy or crossing time zones. Basaglar and lantus have the same amino acid sequence but their folding might be a bit different - they are biosimilar, not biosame, so I would not trust them to be exactly the same. So, if you are happy with your present control, I would not switch - if your present control is good (however one defines this), then a switch cannot make it better, but might make it worse. If you are not happy with your present control, then a switch is reasonable, but a switch to degludec is probably going to be more of an improvement than a switch to the bio-similar insulin. Hope this is helpful Best wishes.
